Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Freemantle

Showing results (31-40 of 174) with videos related to

Pageof 18
Sort By:
BMJ (Clinical Research Ed.)|May 27, 1999
Not playing with a full DEC: why development and evaluation committee methods for appraising new drugs may be inadequateN Freemantle, J Mason
International Journal of Technology Assessment in Health Care|January 1, 1995
Assisted conception techniques. On what basis do health technologies become routinely available when they have been assessed as effective?N Freemantle, I Watt
BMJ (Clinical Research Ed.)|June 15, 1996
Lessons from international experience in controlling pharmaceutical expenditure. II: Influencing doctorsK Bloor, N Freemantle
Health Economics|March 1, 1994
Something rotten in the state of clinical and economic evaluations?N Freemantle, A Maynard
BMJ (Clinical Research Ed.)|February 12, 1994
Conflict of interest. Authors of letters should also disclose interestsA House, N Freemantle
Journal of Clinical Pharmacy and Therapeutics|January 30, 2004
Use of health-related quality of life in prescribing research. Part 2: methodological considerations for the assessment of health-related quality of life in clinical trialsM J Calvert, N Freemantle
Journal of Clinical Pharmacy and Therapeutics|December 4, 2003
Use of health-related quality of life in prescribing research. Part 1: why evaluate health-related quality of life?M J Calvert, N Freemantle
Lancet (London, England)|March 5, 1994
Continuing medical educationI S Watt, N Freemantle
BMJ (Clinical Research Ed.)|October 2, 1993
Prioritising resourcesN Freemantle, T A Sheldon
JAMA|February 10, 1999
Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention StudyJ M Mason, N Freemantle
Pageof 18

Showing results (31-40 of 174) with videos related to

Sort By:
Pageof 18
BMJ (Clinical Research Ed.)|May 27, 1999
Not playing with a full DEC: why development and evaluation committee methods for appraising new drugs may be inadequateN Freemantle, J Mason
International Journal of Technology Assessment in Health Care|January 1, 1995
Assisted conception techniques. On what basis do health technologies become routinely available when they have been assessed as effective?N Freemantle, I Watt
BMJ (Clinical Research Ed.)|June 15, 1996
Lessons from international experience in controlling pharmaceutical expenditure. II: Influencing doctorsK Bloor, N Freemantle
Health Economics|March 1, 1994
Something rotten in the state of clinical and economic evaluations?N Freemantle, A Maynard
BMJ (Clinical Research Ed.)|February 12, 1994
Conflict of interest. Authors of letters should also disclose interestsA House, N Freemantle
Journal of Clinical Pharmacy and Therapeutics|January 30, 2004
Use of health-related quality of life in prescribing research. Part 2: methodological considerations for the assessment of health-related quality of life in clinical trialsM J Calvert, N Freemantle
Journal of Clinical Pharmacy and Therapeutics|December 4, 2003
Use of health-related quality of life in prescribing research. Part 1: why evaluate health-related quality of life?M J Calvert, N Freemantle
Lancet (London, England)|March 5, 1994
Continuing medical educationI S Watt, N Freemantle
BMJ (Clinical Research Ed.)|October 2, 1993
Prioritising resourcesN Freemantle, T A Sheldon
JAMA|February 10, 1999
Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention StudyJ M Mason, N Freemantle
Pageof 18